You are here

Article Text

Article menu

Download PDFPDF

Poster/ePoster Sessions
06. Ovarian cancer
#1028 Impact on survival of crs score in ovarian cancer treated with neoadjuvant chemotherapy
Free
  1. Andres Rave Ramirez,
  2. Maria Laseca Modrego,
  3. Octavio Arencibia Sanchez,
  4. Daniel Gonzalez Garcia-Cano,
  5. Beatriz Navarro Santana,
  6. Alicia Martin Martinez and
  7. Avinash Ramchandani Vaswani
  1. Complejo Hospitalario Universitario Insular Materno Infantil de Canarias, Las Palmas De Gran Canaria, Spain

Abstract

Introduction/Background Ovarian cancer remains the most common cause of mortality in pelvic gynecologic cancer.Neoadjuvant chemotherapy (NACT)followed by surgery has been shown to be an alternative treatment in patients with advanced ovarian cancer who are unlikely to achieve optimal cytoreduction with primary surgery.Successful stratification tools have been created to determine cytoreduction prognosis.The Chemotherapy Response Score(CRS) is intended to be one of them. We will evaluate the impact on OS at 3 and 5 years of patients treated with NACT followed by surgery according to the CRS

Methodology Retrospective analysis of a longitudinal cohort study. All patients diagnosed with FIGO stage IIIC ovarian cancer who received NACT followed by surgery as treatment between 2017–2022 were included.All patients received 4–6 cycles of chemotherapy,carbo-taxol schedule followed by surgery.CRS was analyzed in all of them.A CRS 1 and 2 indicated partial chemotherapy response while CRS score 3 indicated very good response to chemotherapy.Finally,3-and 5-year survival was analyzed according to the CRS

Results A total of 57 patients met the inclusion criteria,representing 40.7% of all stage IIIC ovarian cancers in that period.Mean age was 62 years,75.4% were menopausal and 32.6% of them had a BMI in the obese range.Regarding personal history, 28.6% were hypertensive and 7% were diabetic.Regarding clinicopathological characteristics, the most frequent tumor type was serous carcinoma (93%).A CRS 1–2 was present in 80.7%(n= 46).Clinicopathological characteristics were compared between the CRS 1–2 and CRS 3 groups and no statistically significant differences were found between the two groups.Survival of patients at 3 and 5 years in the CRS 3 group was 100%,while in the CRS 1–2 group it was 68.9% and 53.3%respectively,these differences being statistically significant(Log Rack of 0.04 and 0.009).

View this table:
Abstract #1028 Table 1

Conclusion In our study,presenting a CRS 3 after treatment with NACT followed by surgery is a good prognostic factor with a 3 & 5-year survival of 100%.

Disclosures No disclosures

https://doi.org/10.1136/ijgc-2023-ESGO.694

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.